Atara Biotherapeutics, Inc. 0HIY.L Stock
Atara Biotherapeutics, Inc. Price Chart
Atara Biotherapeutics, Inc. 0HIY.L Financial and Trading Overview
| Atara Biotherapeutics, Inc. stock price | 0.71 USD |
| Previous Close | 2.15 USD |
| Open | 0 USD |
| Bid | 0 USD x N/A |
| Ask | 0 USD x N/A |
| Day's Range | 0 - 0 USD |
| 52 Week Range | 0 - 9.17 USD |
| Volume | 38K USD |
| Avg. Volume | 2.5K USD |
| Market Cap | 533.55K USD |
| Beta (5Y Monthly) | 0.94507 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.645 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
0HIY.L Valuation Measures
| Enterprise Value | 72.76M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.009281587 |
| Price/Book (mrq) | 3.1946511 |
| Enterprise Value/Revenue | 1.266 |
| Enterprise Value/EBITDA | -0.284 |
Trading Information
Atara Biotherapeutics, Inc. Stock Price History
| Beta (5Y Monthly) | 0.94507 |
| 52-Week Change | -64.89% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 9.17 USD |
| 52 Week Low | 0 USD |
| 50-Day Moving Average | 2.4 USD |
| 200-Day Moving Average | 3.84 USD |
0HIY.L Share Statistics
| Avg. Volume (3 month) | 2.5K USD |
| Avg. Daily Volume (10-Days) | 2.84K USD |
| Shares Outstanding | 45.65M |
| Float | 75.79M |
| Short Ratio | N/A |
| % Held by Insiders | 1.62% |
| % Held by Institutions | 103.98% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -454.55% |
| Gross Margin | 121.90% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -46.70% |
| Return on Equity (ttm) | -148.62% |
Income Statement
| Revenue (ttm) | 57.49M USD |
| Revenue Per Share (ttm) | 0.56 USD |
| Quarterly Revenue Growth (yoy) | -83.20% |
| Gross Profit (ttm) | 63.57M USD |
| EBITDA | -256026000 USD |
| Net Income Avi to Common (ttm) | -214968000 USD |
| Diluted EPS (ttm) | -3.645 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 205.41M USD |
| Total Cash Per Share (mrq) | 2.1 USD |
| Total Debt (mrq) | 67.53M USD |
| Total Debt/Equity (mrq) | 103.95 USD |
| Current Ratio (mrq) | 3.303 |
| Book Value Per Share (mrq) | 0.673 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -224330000 USD |
| Levered Free Cash Flow (ttm) | -162083248 USD |
Profile of Atara Biotherapeutics, Inc.
| Country | United Kingdom |
| State | CA |
| City | Thousand Oaks |
| Address | 2380 Conejo Spectrum Street |
| ZIP | 91320 |
| Phone | 805 623 4211 |
| Website | https://www.atarabio.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 330 |
Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Q&A For Atara Biotherapeutics, Inc. Stock
What is a current 0HIY.L stock price?
Atara Biotherapeutics, Inc. 0HIY.L stock price today per share is 0.71 USD.
How to purchase Atara Biotherapeutics, Inc. stock?
You can buy 0HIY.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Atara Biotherapeutics, Inc.?
The stock symbol or ticker of Atara Biotherapeutics, Inc. is 0HIY.L.
How many shares does Atara Biotherapeutics, Inc. have in circulation?
The max supply of Atara Biotherapeutics, Inc. shares is 248.16K.
What is Atara Biotherapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Atara Biotherapeutics, Inc. PE Ratio is now.
What was Atara Biotherapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Atara Biotherapeutics, Inc. EPS is -3.645 USD over the trailing 12 months.